$康方生物(09926)$ 财报电话会议摘要。

Earnings Call Summary | Summit Therapeutics(SMMT.US) Q1 2024 Earnings Conference

财报电话会议摘要 | Summit Therapeutics (SMMT.US) 2024 年第一季度财报会议

富途资讯· 18:33 ·电话会议

The following is a summary of the Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript:

以下是Summit Therapeutics Inc.（SMMT）2024年第一季度财报电话会议记录摘要：

Financial Performance:

财务业绩：

Summit Therapeutics ended Q1 2024 with a cash balance of $157 million, projected to support operations until Q1 2025.

GAAP R&D expenses were $30.9 million, and non-GAAP R&D expenses were $28.5 million.

GAAP G&A expenses reached $11.7 million, with non-GAAP G&A expenses standing at $4.6 million. Most spending is directed at research and development, with $28.3 million approved for the quarter on a non-GAAP basis.

截至2024年第一季度，Summit Therapeutics的现金余额为1.57亿美元，预计将在2025年第一季度之前为运营提供支持。

GAAP研发费用为3,090万美元，非GAAP研发费用为2,850万美元。

GAAP并购支出达到1170万美元，非公认会计准则并购支出为460万美元。大部分支出用于研发，按非公认会计准则计算，本季度批准了2,830万美元。

Business Progress:

业务进展：

The company is actively enrolling patients in two Phase III clinical trials, HARMONi and HARMONi-3, with completion anticipated by the second half of 2024.

The lead investigational compound, ivonescimab, has potential applications across various cancer types, including gynecological tumors, lung cancer, and colorectal cancer.

Phase II ivonescimab data from partner Akeso presented promise across multiple lung cancer settings.

Further exploration of ivonescimab in different indications is being planned, based on insights from ongoing Phase II trials.

The addition of genomicist Dr. Mostafa Ronaghi to the Board of Directors strengthens the company's focus on genomics-based drug development.

该公司正在积极招收患者参加两项三期临床试验，即Harmoni和Harmoni-3，预计将于2024年下半年完成。

主要研究化合物依旺西单抗有可能应用于各种癌症类型，包括妇科肿瘤、肺癌和结直肠癌。

来自合作伙伴Akeso的II期依文西单抗数据为多种肺癌环境带来了希望。

根据正在进行的II期试验的见解，正在计划在不同适应症中进一步探索依文西单抗。

基因组学家莫斯塔法·罗纳吉博士加入董事会加强了公司对基于基因组学的药物开发的关注。

More details: 网页链接{Summit Therapeutics IR}